![](https://endpts.com/wp-content/uploads/2022/09/John-Leonard.jpg)
John Leonard, Intellia Therapeutics CEO
Intellia plots Phase 3 study and a 2026 FDA submission after CRISPR therapy cuts swelling attacks by 98%
Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost entirely eliminated swelling attacks in 10 people with hereditary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.